Ad-hoc announcement pursuant to Article 17 of the Regulation (EU) No. 596/2024

PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchange effective upon the expiry of August 11, 2025

Gräfelfing, August 6, 2025 – The Management Board of PharmaSGP Holding SE (“PharmaSGP”) has been informed today about the decision of the management of the Frankfurt Stock Exchange that the revocation of the admission of the shares of PharmaSGP to trading on the regulated market of the Frankfurt Stock Exchange under ISIN DE000A2P4LJ5, as applied for by PharmaSGP, will become effective upon the expiry of August 11, 2025. PharmaSGP will also make applications to the other stock exchanges on which shares of PharmaSGP are traded in the open market to terminate such trading and inclusion in the open market, if possible, with the expiry of August 11, 2025, or shortly thereafter.

The revocation of the admission to trading (delisting) takes place in the context of the delisting offer by FUTRUE GmbH dated July 14, 2025, the offer period of which will expire on August 11, 2025. As already announced in the ad hoc notification dated June 10, 2025, as part of a delisting agreement with FUTRUE GmbH dated June 10, 2025, PharmaSGP has undertaken, among other things, subject to customary conditions, to support the delisting of PharmaSGP by applying for the revocation of the admission of all PharmaSGP shares to trading on the regulated market of the Frankfurt Stock Exchange before the expiry of the offer period of the delisting offer by FUTRUE GmbH.

CONTACT
cometis AG
Jakob Hafer
Phone: +49-611-20585522
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.